963 related articles for article (PubMed ID: 11301341)
21. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
22. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications.
Cheng L; Neumann RM; Bostwick DG
Cancer; 1999 Nov; 86(10):2102-8. PubMed ID: 10570438
[TBL] [Abstract][Full Text] [Related]
23. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
24. [So-called "superficial" bladder tumors. Which classification in 2003? Part 1: Papillary tumors].
Billerey C; Sibony M
Ann Pathol; 2003 Feb; 23(1):21-33. PubMed ID: 12743497
[TBL] [Abstract][Full Text] [Related]
25. Flat intraepithelial lesions of the urinary bladder.
Cheng L; Cheville JC; Neumann RM; Bostwick DG
Cancer; 2000 Feb; 88(3):625-31. PubMed ID: 10649257
[TBL] [Abstract][Full Text] [Related]
26. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.
Chaux A; Karram S; Miller JS; Fajardo DA; Lee TK; Miyamoto H; Netto GJ
Hum Pathol; 2012 Jan; 43(1):115-20. PubMed ID: 21820145
[TBL] [Abstract][Full Text] [Related]
27. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
29. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.
Jones TD; Cheng L
J Urol; 2006 Jun; 175(6):1995-2003. PubMed ID: 16697785
[TBL] [Abstract][Full Text] [Related]
30. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.
Harnden P; Mahmood N; Southgate J
Lancet; 1999 Mar; 353(9157):974-7. PubMed ID: 10459907
[TBL] [Abstract][Full Text] [Related]
31. [Determination of grade of urothelial carcinoma according to WHO 2004 classification].
Kruslin B; Belicza M
Lijec Vjesn; 2006; 128(7-8):201-6. PubMed ID: 17087133
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma.
Cao D; Vollmer RT; Luly J; Jain S; Roytman TM; Ferris CW; Hudson MA
Urology; 2010 Sep; 76(3):593-9. PubMed ID: 20381131
[TBL] [Abstract][Full Text] [Related]
33. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
34. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
van der Kwast TH
Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
[TBL] [Abstract][Full Text] [Related]
35. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
38. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
39. [So-called "superficial" bladder tumors. Which classification in 2003? Part 2: Flat urothelial lesions].
Sibony M; Billerey C
Ann Pathol; 2003 Feb; 23(1):35-45. PubMed ID: 12743498
[TBL] [Abstract][Full Text] [Related]
40. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
